Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to...
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 trial assessing the investigational use of Dupixent (dupilumab) in children aged 1 to...
Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA)...
Regeneron Pharmaceuticals, Inc and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
